COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,552 Articles (22,400 medRxiv, 8,152 bioRxiv)

Most recent first Previous |  Page 313: Articles 3121-3130  | Next

An engineered A549 cell line expressing CD13 and TMPRSS2 is permissive to clinical isolate of human coronavirus 229E
Lie, L. K., Synowiec, A., Mazur, J., Pyrc, K.
10.1101/2023.07.21.545505 — Posted: 2023-07-21
Complete Protection from SARS-CoV-2 Lung Infection in Mice Through Combined Intranasal Delivery of PIKfyve Kinase and TMPRSS2 Protease Inhibitors
Kant, R., Kareinen, L., Ojha, R., Strandin, T., Saber, S. H., Lesnikova, A., Kuivanen, S., Sironen, T., Joensuu, M., Vapalahti, O., Kirchhausen, T., Kipar, A., Balistreri, G.
10.1101/2023.07.19.549731 — Posted: 2023-07-20
No evidence for the association between COVID-19 and neuroinflammation: A diffusion basis spectrum imaging study.
Zhang, W., Gorelik, A. J., Wang, Q., Norton, S. A., Hershey, T., Bijsterbosch, J. D., Bogdan, R.
10.1101/2023.07.20.549891 — Posted: 2023-07-20
Structure, Dynamics and Free Energy Studies on the Effect of Spot Mutations on SARS-CoV-2 Spike Protein Binding with ACE2 Receptor
Rucker, G., Qin, H., Zhang, L.
10.1101/2023.07.19.549772 — Posted: 2023-07-20
Induction of antiviral gene expression by cyclosporine A, but not inhibition of cyclophilin A or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line
Mamatis, J. E., Gallardo-Flores, C. E., Walsh, T., Sangwan, U., Colpitts, C. C.
10.1101/2023.07.20.549884 — Posted: 2023-07-20
Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations
Westberg, M., Su, Y., Zou, X., Huang, P., Rustagi, A., Garhyan, J., Patel, P. B., Fernandez, D., Wu, Y., Ning, L., Beck, A., Karim, M., Hao, C., Saenkham-Huntsinger, P., Tat, V., Drelich, A., Peng, B.-H., Einav, S., Tseng, C.-T. K., Blish, C., Lin, M. Z.
10.1101/2023.07.19.549739 — Posted: 2023-07-20
Epigenetic Age Acceleration in Surviving versus Deceased COVID-19 Patients with Acute Respiratory Distress Syndrome following Hospitalization
Bejaoui, Y., Humaira Amanullah, F., Saad, M., Taleb, S., Bradic, M., Megarbane, A., Ait Hssain, A., Abi Khalil, C., El Hajj, N.
10.1101/2023.07.18.549478 — Posted: 2023-07-19
Intranasal lavage with hypochlorous acid safely reduces the symptoms in the ambulatory patient with COVID-19.
Abner, M. L.
10.1101/2023.07.17.23292426 — Posted: 2023-07-18
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
Liu, Y., Yong, X., Liu, J., Zeng, Y., Nie, J., Cui, X., Wang, T., Wang, Y., Chen, Y., Kang, W., Yang, Z.
10.1101/2023.07.17.23292762 — Posted: 2023-07-18
Identification of predictive patient characteristics for assessing the probability of COVID-19 in-hospital mortality
Rajwa, B., Naved, M. M. A., Adibuzzaman, M., Grama, A. Y., Khan, B. A., Dundar, M., Rochet, J.-C.
10.1101/2023.07.16.23292738 — Posted: 2023-07-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).